Testing with combined biopsy method improves prostate cancer diagnosis in NIH study | National Institutes of Health (NIH)

Testing with combined biopsy method improves prostate cancer diagnosis in NIH study | National Institutes of Health (NIH): Improved diagnosis could reduce the risk of both overtreatment and undertreatment of the disease

Comments

Post a Comment

Popular posts from this blog

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more

ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management

Image
New Hope for Aggressive Prostate Cancer: Advances in Understanding and Treating Neuroendocrine Prostate Cancer Revolutionary diagnostic tools and promising new therapies offer renewed hope for patients with treatment-resistant disease What Patients Need to Know For most men with prostate cancer, treatments targeting the androgen receptor (AR) pathway—including hormone therapy and newer drugs like enzalutamide and abiraterone—are highly effective. However, as these treatments have become more successful, doctors have observed an important but concerning phenomenon: some cancers develop resistance by essentially changing their identity. This transformation, called neuroendocrine prostate cancer (NEPC), represents one of the most aggressive forms of the disease. At the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Himisha Beltran from Dana-Farber Cancer Institute presented groundbreaking research that offers new hope for patients facing this challenging ...
Read more

What to Expect and Plan for in Pluvicto Treatment at UCSD:

Image
What to Expect and Plan for in Pluvicto Treatment: A Comprehensive Guide for Prostate Cancer Patients Special Report for the IPCSG Newsletter Major FDA Expansion Opens Treatment to More Patients On March 28, 2025, the FDA expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay chemotherapy. This expanded indication approximately triples the number of patients eligible to receive Pluvicto. This groundbreaking development means that many more patients can now access this innovative treatment earlier in their disease progression, potentially before requiring chemotherapy. Understanding Pluvicto: How It Works Pluvicto is a "theranostic" medicine that combines diagnostic and therapeutic capabilities. It's a type of radiation that specif...
Read more